BridgeBio Pharma, Inc. Increase (Decrease) in Accounts Payable
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Accounts Payable of -$9.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.86M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$7.17M, a 140.81% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $17.52M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$7.43M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for fiscal 2025 was $26.61M, a 1659.85% increase from fiscal 2024.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.51M, a 45.61% decline from fiscal 2023.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for fiscal 2023 was $2.78M.
- BridgeBio Pharma, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$349.00K, a 112.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$9.03M 10-Q · filed 2026-08-10 | $8.50M derived: sum of 3 quarters · filed 2026-08-10 | $1.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$7.17M 10-Q · filed 2026-05-07 | $10.36M derived: sum of 2 quarters · filed 2026-05-07 | $2.92M derived: sum of 3 quarters · filed 2026-05-07 | $1.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $17.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.09M derived: sum of 2 quarters · filed 2026-02-24 | $9.04M derived: sum of 3 quarters · filed 2026-08-10 | $26.61M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$7.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$8.49M derived: sum of 2 quarters · filed 2026-08-10 | $9.08M 10-Q · filed 2025-10-29 | $5.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $16.52M 10-Q · filed 2026-08-10 | $12.77M derived: sum of 3 quarters · filed 2026-08-10 | $9.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $17.57M 10-Q · filed 2026-05-07 | $13.83M derived: sum of 2 quarters · filed 2026-05-07 | $10.22M derived: sum of 3 quarters · filed 2026-05-07 | $25.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.35M derived: sum of 2 quarters · filed 2026-02-24 | $7.44M derived: sum of 3 quarters · filed 2026-02-24 | $1.51M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $11.18M derived: sum of 2 quarters · filed 2025-10-29 | $5.26M 10-Q · filed 2025-10-29 | $11.44M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $14.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $8.86M 10-Q · filed 2025-08-05 | $15.04M derived: sum of 3 quarters · filed 2026-02-24 | $15.74M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$5.93M 10-Q · filed 2025-04-29 | $257.00K derived: sum of 2 quarters · filed 2026-02-24 | $951.00K derived: sum of 3 quarters · filed 2026-02-24 | $653.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.88M derived: sum of 2 quarters · filed 2026-02-24 | $6.58M derived: sum of 3 quarters · filed 2026-02-24 | $2.78M 10-K · filed 2026-02-24 |
| 2023-09-30 | $694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $396.00K derived: sum of 2 quarters · filed 2024-11-12 | -$3.40M 10-Q · filed 2024-11-12 | -$2.03M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$298.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$4.10M 10-Q · filed 2024-08-01 | -$2.72M derived: sum of 3 quarters · filed 2025-02-20 | -$1.36M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$3.80M 10-Q · filed 2024-05-02 | -$2.42M derived: sum of 2 quarters · filed 2025-02-20 | -$1.06M derived: sum of 3 quarters · filed 2025-02-20 | -$2.33M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $2.74M derived: sum of 2 quarters · filed 2025-02-20 | $1.47M derived: sum of 3 quarters · filed 2025-02-20 | -$349.00K 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $89.00K derived: sum of 2 quarters · filed 2023-11-02 | -$1.73M 10-Q · filed 2023-11-02 | -$252.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$3.09M 10-Q · filed 2023-08-03 | -$1.62M derived: sum of 3 quarters · filed 2024-02-22 | -$13.28M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$1.81M 10-Q · filed 2023-05-04 | -$341.00K derived: sum of 2 quarters · filed 2024-02-22 | -$12.01M derived: sum of 3 quarters · filed 2024-02-22 | -$773.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$10.19M derived: sum of 2 quarters · filed 2024-02-22 | $1.04M derived: sum of 3 quarters · filed 2024-02-22 | $2.83M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$11.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$432.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.36M 10-Q · filed 2022-11-03 | $78.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $11.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.03M 10-Q · filed 2022-08-04 | $11.74M derived: sum of 3 quarters · filed 2023-02-23 | $8.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.79M 10-Q · filed 2022-05-05 | $510.00K derived: sum of 2 quarters · filed 2023-02-23 | -$2.93M derived: sum of 3 quarters · filed 2023-02-23 | -$3.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$4.72M derived: sum of 2 quarters · filed 2023-02-23 | -$4.97M derived: sum of 3 quarters · filed 2023-02-23 | -$735.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | -$3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$3.69M derived: sum of 2 quarters · filed 2021-11-04 | $547.00K 10-Q · filed 2021-11-04 | -$871.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.98M 10-Q · filed 2021-08-05 | $2.56M derived: sum of 3 quarters · filed 2022-02-25 | -$820.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.23M 10-Q · filed 2021-05-06 | $2.82M derived: sum of 2 quarters · filed 2022-02-25 | -$569.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.53M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$4.80M derived: sum of 2 quarters · filed 2022-02-25 | -$2.71M derived: sum of 3 quarters · filed 2022-02-25 | -$4.66M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.29M derived: sum of 2 quarters · filed 2020-11-05 | -$3.24M 10-Q · filed 2020-11-05 | $4.51M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $146.00K 10-Q · filed 2020-08-11 | $7.89M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$1.95M 10-Q · filed 2020-05-14 | $5.79M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $16.70M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $8.95M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $1.58M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |